Long-term clinical outcomes with <i>Clostridium butyricum</i> MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).
Sumanta Kumar Pal(City Of Hope National Medical Center), Miguel Zugman(City of Hope), Xiaochen Li(City of Hope), Alex Chehrazi‐Raffle(City of Hope), Motomichi Takahashi, Jennifer Karmouch(Centre National de la Recherche Scientifique), Robert L. Jeng(City of Hope), Seiya Higashi, Peter P. Lee(Moffitt Cancer Center), Hedyeh Ebrahimi(City of Hope), Xinran Qi(City of Hope), Vitor Góes(City of Hope), Thomas P. Parks(Boehringer Ingelheim (United States)), JoAnn Hsu(City of Hope), Nazli Dizman(The University of Texas MD Anderson Cancer Center), Salvador Jaime-Casas(City of Hope), Kentaro Oka, T. Dorff(City of Hope), Antonio Cruz Gomes(City of Hope)
Cited by 0
Related Papers
Transcriptional Regulation of the Intercellular Adhesion Molecule-1 Gene by Inflammatory Cytokines in Human Endothelial Cells
|Journal of Biological Chemistry|1995|540
Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy
|Journal of Immunotherapy|2002|299
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|184
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
|Clinical Cancer Research|2011|109